Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 1,347 Shares of Stock

by · The Cerbat Gem

Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) SVP Paula Green sold 1,347 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $64,656.00. Following the sale, the senior vice president now directly owns 114,147 shares of the company’s stock, valued at $5,479,056. This represents a 1.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Paula Green also recently made the following trade(s):

  • On Wednesday, November 6th, Paula Green sold 5,519 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $246,147.40.
  • On Monday, November 4th, Paula Green sold 1,057 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $43,928.92.
  • On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10.
  • On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The stock was sold at an average price of $46.94, for a total transaction of $13,941.18.

Twist Bioscience Stock Down 8.3 %

Shares of NASDAQ:TWST opened at $38.96 on Friday. The company has a 50 day moving average of $43.90 and a 200 day moving average of $45.88. Twist Bioscience Co. has a 12 month low of $18.80 and a 12 month high of $60.90.

Analyst Ratings Changes

TWST has been the subject of several analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, Barclays reduced their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Check Out Our Latest Stock Analysis on Twist Bioscience

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Signaturefd LLC increased its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the 2nd quarter worth $43,000. Blue Trust Inc. raised its position in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience during the 2nd quarter worth $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

(Get Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Featured Stories